Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.
Press releases published on August 6, 2025
EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments
GlobeNewswire
·
August 6, 2025
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO …
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
GlobeNewswire
·
August 6, 2025
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that …
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
GlobeNewswire
·
August 6, 2025
Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation Leading academic institutions are evaluating BXCL- …
Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
GlobeNewswire
·
August 6, 2025
NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, …
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 6, 2025
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres …
Bioventus Reports Second Quarter Financial Results
GlobeNewswire
·
August 6, 2025
Q2 reported revenue of $147.7 million declined 2.4%; Organic* revenue advanced 6.2% Second quarter diluted earnings per share was $0.11 compared to a diluted loss per share of $0.40 in the prior-year period Non-GAAP earnings* of $0.21 per share increased …
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
August 6, 2025
– Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with …
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
GlobeNewswire
·
August 6, 2025
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of …
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
GlobeNewswire
·
August 6, 2025
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN …
Fortrea Reports Second Quarter 2025 Results
GlobeNewswire
·
August 6, 2025
For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 million GAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment charge Adjusted EBITDA of $54.9 million GAAP and adjusted net (loss) income per …
Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
GlobeNewswire
·
August 6, 2025
SOLANA BEACH, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today …
SimpliFed Launches Inaugural National Mastitis Awareness Day During National Breastfeeding Month
GlobeNewswire
·
August 6, 2025
ITHACA, NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- SimpliFed, the leading virtual maternal health leader in breastfeeding and baby feeding support, has launched the first inaugural National Mastitis Awareness Day, on the forest Wednesday in August, …
Forte Medical National Survey Announcement
GlobeNewswire
·
August 6, 2025
LONDON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- UK based Medical Technology company Forte Medical is launching a national survey of women in the UK, to ascertain their exposure to urine sampling retests and immediate empirical broad spectrum prescribing, …
Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medicine Advanced Therapy (RMAT) van de FDA krijgt voor de behandeling van recidief/refractair mantelcellymfoom
GlobeNewswire
·
August 6, 2025
Mechelen, België; 6 augustus 2025, 7.30 uur CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext …
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors
GlobeNewswire
·
August 6, 2025
Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific. Buchanan, formerly a venture capitalist with the Vertical Group, is also an active …
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
GlobeNewswire
·
August 6, 2025
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext …
Communiqué de presse : Sanofi finalise l’acquisition de Vigil Neuroscience, Inc.
GlobeNewswire
·
August 6, 2025
Sanofi finalise l’acquisition de Vigil Neuroscience, Inc. Paris, le 6 août 2025. Sanofi annonce la finalisation de l’acquisition de Vigil Neuroscience, Inc. (« Vigil »). Cette acquisition renforce le pipeline de Sanofi en neurologie avec le VG-3927, un …
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
GlobeNewswire
·
August 6, 2025
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition strengthens Sanofi’s early-stage pipeline in neurology with VG- …
BriaCell Announces Proposed Effective Date of Share Consolidation
GlobeNewswire
·
August 6, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to …